This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision

All amounts are in US dollars

QUÉBEC CITY, Nov. 1, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the appointment of Jude Dinges as Senior Vice President, Chief Commercial Officer, thus reaffirming its new vision of becoming a specialty biopharmaceutical commercially operating company.

"Over the last few months, we have conducted an in-depth review of our R&D and corporate activities. This has led to a comprehensive strategic growth plan focused on achieving our goal of transforming Aeterna Zentaris into a biopharmaceutical operating company through the commercialization of our pipeline, as well as through actively pursuing in-licensing and acquisition opportunities", said David Dodd, President and CEO of Aeterna Zentaris. "Jude's appointment is in line with this new vision. His more than 30 years experience in pharmaceutical and biologics commercial development will be very valuable as we are in the process of bringing macimorelin acetate to market as the first approved oral product for evaluating growth hormone deficiency in adults. He will also be responsible for future commercial opportunities with a view of ensuring sustained growth. We are delighted that Jude is joining our management team, and we look forward to his contributions to our growth and development."

Jude Dinges added, "I'm very excited to join the Aeterna Zentaris team at this important time in its history. With a near-term NDA filing, a promising oncology pipeline and a talented leadership team, I feel Aeterna Zentaris holds great promise as a commercial entity, offering solutions to the unmet medical needs of patients and the healthcare professionals who serve them."

New Strategic Vision
  • Focus on the successful development and commercialization of Company pipeline:
    • Macimorelin acetate (AEZS-130)
      • Submission of NDA to the FDA as the first approved oral product for the evaluation of adult growth hormone deficiency
      • Preparation for its commercial launch (sales and marketing strategy)
      • Commercial launch and brand development
    • Zoptarelin doxorubicin (AEZS-108)
      • Increased efforts regarding patient enrollment for Phase 3 ZoptEC ( Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy
      • Co-development agreement with Ergomed as CRO who has agreed to assume 30% of external costs of the trial (up to $10 million)
    • AEZS-120
      • Approval from Danish regulatory authorities for a Phase 1 proof-of-concept trial as an oral prostate cancer vaccine
      • Initiation of a Phase 1 clinical trial
  • Focus on successful in-/out-licensing and acquisition opportunities:
    • Identification of companies with already marketed products
    • Integration of commercial activities
    • Leveraging of sales force

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.30 -1.60%
FB $116.79 0.05%
GOOG $692.63 0.23%
TSLA $245.17 -1.00%
YHOO $36.55 -0.11%


Chart of I:DJI
DOW 17,750.91 -79.85 -0.45%
S&P 500 2,066.13 -9.68 -0.47%
NASDAQ 4,777.1220 -28.1690 -0.59%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs